RECAMO

The work of the Research Center for Applied Molecular Oncology (RECAMO) is focused on cancer biology. RECAMO is represented by a multidisciplinary team consisting of Czech and foreign researchers and medical specialists working within this cutting edge workplace.

„Research is meeting the unmet needs of our patients.“

doc. MUDr. Tomáš Kazda, Ph.D.

1Contacts

Director for Science & Research

doc. MUDr. Tomáš Kazda, Ph.D.

Scientific director of RECAMO

RNDr. Bořivoj Vojtěšek, DrSc.

2First-rate Cancer Research Center

Seven working groups have been operating at RECAMO since 2020. They have been conducting a long-term research within specific areas of cancer biology. RECAMO is located in the Morávek Pavilion. Laboratories on each of its floors respond to the specific requirements of research activity.

The center is equipped with devices for high-throughput methods of genome and proteome analysis as well as for accurate analytical measurements and morphological studies. Key devices and technical equipment of the centre operate on the basis of so-called “core facility”, i.e. centralised shared resources, which are operated by specialists.

The devices deal with:

  • mass spectrometry,
  • analysis of nucleic acids,
  • protein production and purification,
  • histology and microscopy,
  • flow cytometry,
  • tissue cultures.

3Projects

  • MEYS, European Structural and Investment Funds, CZ.02.2.69/0.0/0.0/18_053/0017836; 2021-2022
    Promoting the development of young MMCI researchers through international mobility.
    Investigator: assoc. prof. Roman Hrstka, M.Sc., Ph.D.
     
  • MEYS, European Regional Development Fund, CZ.02.1.01/0.0/0.0/16_019/0000868; 2018-2023
    Molecular, cellular and clinical approach to healthy ageing (ENOCH).
    Co-investigator: RNDr. Bořivoj Vojtěšek, DrSc.
     
  • GACR 21-13188S; 2021-2023
    Metabolomics and proteostasis in cancer stem cells.
    Principal investigator: Philip John Coates, Ph.D.
     
  • AZV CR NU21-08-00078; 2021-2024
    Electrochemical biosensor for analysis of DNA point mutations in colorectal cancer.
    Principal investigator: Martin Bartošík, M.Sc., Ph.D.
     
  • AZV CR NU21-09-00031; 2021-2024
    Development of new effective strategy to identify high-risk women for endometrial cancer.
    Principal investigator: assoc. prof. Roman Hrstka, M.Sc., Ph.D.
     
  • AZV CR NU21-08-00057; 2021-2024
    Electrode biochip for HPV screening in cervical precancerous lesions.
    Co-investigator: Martin Bartošík, M.Sc., Ph.D
     
  • AZV CR NV18-03-00339; 2018-2021
    Predicting response to checkpoint inhibitors using complex molecular characteristic and immunoprofiling in solid tumors.
    Principal investigator: prof. Rostislav Vyzula, M.D., CSc.
     
  • GACR 19-03796S; 2019-2021
    Mechanisms of stress response in cancer cells.
    Principal investigator: RNDr. Bořivoj Vojtěšek DrSc.
     
  • GACR 19-02014S; 2019-2021
    Identification of determinants associated with metastatic colorectal cancer in relation to Anterior gradient 2.
    Principal investigator: assoc. prof. Roman Hrstka, M.Sc., Ph.D.
     
  • GACR 19-06530S; 2019-2021
    Unravelling the regulation and interactions of p63.
    Principal investigator: Philip John Coates, Ph.D.
     
  • GACR 19-18177Y; 2019-2021
    Mechanism of non-mutational p53 inactivation in human cancers and its implication for cancer therapy.
    Principal investigator: Lucia Hároníková, M.Sc., Ph.D.

4Research groups

Research group of Bořivoj Vojtěšek

Immune system checkpoints are effective targets for cancer therapy. In particular, antibody-based PD-L1 blockage restores immune response and increases anti-tumour immune activity in cancer patients. However, despite some successes, many patients show minimal response, or develop resistance to this therapy. HSP90 is a key molecular chaperone that stabilises several mutant proteins in tumour cells and thus helps to overcome the stress generated by genetic instability. Its “client” proteins include various receptors and/or signalling proteins, many of which are targets for anti-cancer therapy. In one of our research areas, we focus on identifying how HSP90 inhibitors (HSP90i) modify levels of “client” proteins that control the sensitivity/resistance of cancer cells to immune attack. Thus, we are studying the mechanisms of immune activation by HSP90i at multiple levels to provide a comprehensive view of the underlying principles, allowing combination immunotherapeutic approaches in the future.

We also focus on understanding the key ways by which wild type p53 protein, the main tumour suppressor in human cancer, can be inactivated. p53 is mutated in 50 % of cancers and, whilst the other half keeps wild type p53, its function is abrogated by other mechanisms. We are using screening methods such as CRISPR-CAS9 activation/knock-out libraries to describe possible mechanisms of p53 inactivation. Moreover, by using chromatin immunoprecipitation followed by next generation sequencing, we study p53 function as a transcription factor. Modulations in the ability of p53 to specifically bind p53 target genes can lead to inappropriate cellular outcomes and we try to understand how specific binding can be regulated. We also investigate the main p53 negative regulators, HDM2 and HDMX, by studying their protein-protein and protein-RNA interactions and we try to understand a complex regulatory loop in which HDM2 and HDMX switch from negative to positive regulators. By elucidating these questions of p53 inactivation, we lead to better targeted therapy based on p53 reactivation alone or in combined treatment.

The last subject of our laboratory is focussed on studying new potential therapeutic strategies for cancer treatment, using techniques of advanced molecular biology to elucidate mechanisms of action of experimental therapeutics. We work on preclinical testing of new low-molecular weight inhibitors and therapeutic antibodies for targeted therapy. We also study signalling pathways crucial for cancer cell response to therapy and their deregulation in various cancer types. Our understanding of these cellular processes is pivotal for choosing the right therapeutic option and its success.

Scientific director of RECAMO
Research group leader

RNDr. Bořivoj Vojtěšek, DrSc.

Research group of Roman Hrstka 

Our research team focuses on the identification and validation of novel tumour biomarkers, which can come in many forms, e.g. proteins, DNA or RNA, and should ideally be specific to a particular type of cancer and not be present in normal tissues or healthy individuals.

Based on their application, cancer biomarkers can be classified as i) diagnostic, indicating a presence of cancer in a patient; ii) predictive, predicting response to specific therapeutic interventions; iii) prognostic, informing physicians about the risk of clinical outcomes and, some but not all can be exploited as iv) therapeutic targets. We intend to identify, evaluate and put into clinical practice specific tumour biomarkers allowing for the improvement of recent diagnostic methods, monitoring of minimal residual disease, detection of metastasis presence or predict the risk of their development, and the application as therapeutic targets. Besides using the state-of-the-art technologies when analysing these biomarkers, we also develop our own methodological strategies and technologies for their detection, especially electrochemical DNA and RNA biosensors, representing a simple, rapid and inexpensive alternative to current methods.

Research group leader
Senior researcher

doc. Mgr. Roman Hrstka, Ph.D.

Research group of Philip Coates

The research group is focused on two related areas of cancer biology; the role of p63 in cancer formation, progression and resistance to treatment, and the biology of cancer stem cells. p63 is a member of a family of related proteins (p53, p63 and p73) and is present at high levels in squamous cell carcinomas and some other types of cancer.

High levels of p63 are associated with therapy failure, metastasis and death of patients. We are investigating the mechanisms that regulate p63, with the long-term intention that blocking specific pathways that cause increased p63 in cancer could be used therapeutically. In particular, we have found that some drugs that are widely used for treating non-cancer conditions also influence p63. Another aspect of this research tries to identify proteins that interact with p63 (including the other family members, p53 and p73) to regulate its activity. Our studies are also showing that p63 has roles in other cancer types, including about 50% of breast cancers and a small percentage of prostate cancers, where it acts as a regulator of cancer stem cells, our other main topic of research.

Cancer stem cells are proposed to be a unique sub-population of cancer cells that are responsible for overall growth of the tumour, especially for tumour spread to other sites in the body, and are relatively resistant to the common therapies used for most cancer patients (radiotherapy and chemotherapy). The existence of such tumour cell populations has been demonstrated many times, using a variety of different markers to identify these cells. However, it has become apparent that each marker identifies a different population of cells and that cancer stem cells are not a fixed population as originally thought, but may change their properties according to the situation they find themselves in. We are investigating whether we can identify specific properties that accurately define the cancer stem cell population in most or all cancers. The studies ask whether cancer stem cells have differences in their metabolism (specifically, in protein production and how they use glucose to produce energy). The ability to identify universal differences between cancer stem cells and the rest of the tumour cells would help both to study these specific cells in more detail, and to suggest drugs that selectively target these cells in cancer therapy.

Research group leader
Senior researcher

Philip John Coates, Ph.D.

Research group of Lenka Hernychová

The aim of clinical proteomics is to acquire detailed information about qualitative and quantitative alterations in proteins in the studied proteomes and about their connection with physiological and pathological changes. This knowledge can be used to identify markers suitable for early diagnosis or prediction of response to cancer therapy.

The activities of the research group involve its own research or in cooperation with clinicians and domestic or foreign scientific institutions. In addition, this group also provides service analyzes and contracted research. The research is focused on performing proteomic analyzes of samples related to cancer and aging, especially the detection of glycosylations and glycoproteins presented in sera and tissues of patients with solid tumors. Further goals include mapping of tyrosine kinase activity in tumors and also structural proteomic analysis based on protein-ligand interactions measured by the method based on the exchange of hydrogen for deuterium.

Research group leader
Senior researcher

prof. Ing. Lenka Hernychová, Ph.D.
RECAMO

Junior researcher

Ing. Tomáš Henek
RECAMO

Junior researcher

Jaromír Novák

RECAMO

Ph.D. student

Mgr. Adam Paulin Urminský

Research group of Petr Müller

Increasing demands on the maintenance of protein homeostasis is one of the basic features of a tumour cell. Genome instability, high mutation frequency, and increased proteosynthesis lead to activation of stress signalling and increased production and activation of chaperones on which the tumour cells become dependent. Thus, tumours exhibit increased expression of stress-induced chaperones, represented mainly by Hsp70 and Hsp90.

In addition to changes in gene expression, pro-oncogenic chaperone activities are also enhanced by the formation of multimeric chaperone complexes. Therefore, one of our goals is to elucidate the prooncogenic behaviour of chaperones. Our project is focused on the analysis of posttranslational modifications of chaperones in tumours, their interactions and the effect on unstable oncoproteins. Another area of our research is stress signalling. Stress response is a key feature of cancer cells that ensures enhanced protein synthesis, compensates genomic instability and protects cancers from therapy induced stress. Heat shock factor-1 (HSF1) is a major stress-response transcription factor, and its activity is markedly enhanced in cancer. Proteotoxic stress activates HSF1 by conformational changes, leading to assembly of HSF1 trimers that bind DNA and control target gene expression. Although the function of HSF1 in transcription is known, the mechanisms leading to HSF1 activation and enhanced stress response in tumours are unclear. The research goal of our group is to describe the mechanisms that a tumour cell uses to maintain protein homeostasis. The aim of the research project focused on HSF1 is to reveal the mechanisms leading to HSF1 activation. Using structural proteomics, we describe the conformational changes that are responsible for its activation. The specific role of HSF1-regulated genes for tumour transformation is studied by gene expression analysis.

Research group leader
Senior researcher

MUDr. Petr Müller, Ph.D.

Research group of Bioinformatics

The Bioinformatics Research Group is focused on highly specialized analyses of a bioinformatics and statistical dates for individual departments of the MOU, other research groups and external collaborators. The department is also focused on molecular modelling and molecular dynamics of proteins and the development of statistical and analytical software's.

Research group leader
Senior researcher

Mgr. Bc. Filip Zavadil Kokáš, Ph.D.

Research group of Marek Svoboda

Cellular immunity plays a key role in the eradication of tumors; however, tumor cells can escape the immune system in the process called immunoediting. In contrast, immunotherapy is a strategy to reactivate and induce the immune system's ability to recognize and kill tumor cells. Immunotherapy is therefore a very dynamic and promising method of anticancer treatment for many types of tumors.

The actual interaction of immune and tumor cells occurs in the tumor microenvironment, which includes all cells as well as non-cellular components of tumor tissue and its immediate surroundings. Tumor microenvironment is characterized by acidic pH, hypoxia or low levels of nutrients, which are factors causing cellular stress, including the so-called "endoplasmic reticulum (ER) stress". Thus, it can be hypothesized that ER stress may play a major role both in the process of tumor immunoediting and in response to immunotherapy.

Therefore, our goal is to study the effect of ER stress on the immune status of the tumor, immunoediting and, last but not least, on the effectiveness of immunotherapy in renal and ovarian carcinomas.

Research group leader
Director of MMCI

prof. MUDr. Marek Svoboda, Ph.D.
RECAMO

Ph.D. student

Mgr. Lukáš Moráň
RECAMO

Researcher

Mgr. Kateřina Vašíčková

RECAMO

Researcher – student

Mgr. Barbora Vavrušáková

5Studies

  • Kateřina Ondrášková (FaSci MU) – topic: Monitoring of minimal residual disease in patients with pancreatic cancer. – supervisor: doc. Mgr. Roman Hrstka, Ph.D.
  • Petra Mikušová (FaSci MU) – topic: The detection of AGR proteins in extracellular space of human tumours. – supervisor: Mgr. Veronika Brychtová, Ph.D. (completed 2018)
  • Andrea Martišová (FaSci MU) – topic: The role of transgelin in tumor cells. – supervisor: doc. Mgr. Roman Hrstka, Ph.D. (completed 2018)
  • Daniel Nesrsta (FaSci MU) – topic: Organometallic compounds in the therapy of tumor diseases. – supervisor: doc. Mgr. Roman Hrstka, Ph.D. (completed 2018)
  • Lucia Janáčová (FaSci MU) - topic: Mechanisms of endocrine resistance in breast cancer. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2016)
  • Matej Hropko (FaSci MU) - topic: Importance of genomics, transcriptomics and proteomics in determining medulloblastoma molecular subgroups. - supervisor BP: Mgr. Marta Nekulová, Ph.D. (completed 2016)
  • Ondřej Vacek (FaSci MU) - topic: Cancer cell response to proteotoxic stress. - supervisor: Mgr. Michal Pastorek, Ph.D. (completed 2016)
  • Lucie Bienová (FaMed MU) - topic: Verification of acute toxicity model for the bladder and rectum in Rapid Arc of prostate cancer. - supervisor: MUDr. Pavel Krupa. (completed 2015)
  • Kateřina Bustová (FaMed MU) - topic: Verification of acute toxicity model for the bladder and rectum in 3D CRT of prostate cancer. - supervisor: MUDr. Pavel Krupa. (completed 2015)
  • Barbora Šustáčková (FaMed MU) - topic: Verification of acute toxicity model for the bladder and rectum in IMRT of prostate cancer. - supervisor: MUDr. Pavel Krupa. (completed 2015)
  • Eliška Stuchlíková (FaSci MU) - topic: Optimization of the proliferation of cell line derived from ovarian cancer resistant to cisplatin. - supervisor: prof. Ing. Lenka Hernychová, Ph.D. (completed 2015)
  • Oliver Šimončík (FaSci MU) - topic: Relationship between protein homeostasis and activation transcript faktors HSF. - supervisor: MUDr. Petr Muller, Ph.D. (completed 2015)
  • Alena Kopková (FaSci MU) - topic: The role of protein p53/47 in endoplasmic reticulum stress. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2015)
  • Sabina Oweisová (FaSci MU) - topic: Application of electroanalytical methods in molecular oncology. - supervisor: Mgr. Martin Bartošík, Ph.D. (completed 2015)
  • Petr Lapčík (FaSci MU) - topic: SWATH-MS method and its application in proteomics analysis of breast cancer. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2015)
  • Pavlína Mrhálková (FaSci MU) - topic: The role of p63 isoforms in tumor cell chemosensitivity. - supervisor: Mgr. Jitka Holčáková, Ph.D. (completed 2014)
  • Václav Hrabal (FaSci MU) - topic: The role of p63 protein in tumorigenesis. - supervisor: Mgr. Jitka Holčáková, Ph.D. (completed 2014)
  • Karolína Zoufalová (FaSci MU) - topic: Signaling pathways in breast cancer metastasis and their investigation using targeted proteomics. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2014)
  • Anna Odehnalová (FaSci MU) - topic: Mechanisms responsible for tamoxifen resistance and potential biomarkers. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2014)
  • Kateřina Ceralová (FaSci MU) - topic: The role of hormones in tumor development, the role of androgen receptors in AGR2 signaling in breast cancer. - supervisor: Mgr. Veronika Brychtová (completed 2014)
  • Helena Ďuríková (FaSci MU) - topic: Detection and identification of small non-coding RNAs in human body liquids. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2014)
  • Markéta Stejskalová (FaSci MU) - topic: Does expression of p63 protein contributes to the formation of cancer stem cells? - supervisor: Mgr. Jitka Holčáková, Ph.D. (completed 2014)
  • Vendula Šromová (FaSci MU) - topic: alpha-B crystallin and its relation to cancer. - supervisor: RNDr, Bořivoj Vojtěšek, DrSc. (completed 2014)
  • Monika Diblíková (FaSci MU) - topic: The function of CD105 protein in tumor development. - supervisor: Mgr. Petr Beneš, Ph.D. (completed 2013)
  • Petra Kovaříková (FaSci MU) - topic: Proteases of extracellular matrix: Functions and methods of study. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2013)
  • Zuzana Bábovská (FaSci MU) - topic: Thymosin protein family and their role in tumorigenesis. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2013)
  • Michal Řiháček (FaSci MU) - topic: Immunochemical and microbiological determination of plasma and erythrocyte folates and the influence of antifolate therapeutics. - supervisor: doc. MUDr. Dalibor Valík, Ph.D. (completed 2012)
  • Josef Maryáš (FaSci MU) - topic: The role of proteins involved in NFkappaB pathway in cancer metastasis. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2012)
  • Jiřina Čípková (FaSci MU) - topic: Autophagy and characterization of anti-ATG4A antibody epitopes using "phage display" method“. - supervisor: Mgr. Pavla Bouchalová, Ph.D. (completed 2012)
  • Lucia Sommerová (FaSci MU) - topic: The role of AGR2 protein in the malignant transformation of the cell. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2012)
  • Lenka Příhodová (FaSci MU) - topic: Inflammatin and cancer. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2012)
  • Květa Pilařová (FaSci MU) - topic: Significance of p53/47 protein in tumours. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2011)
  • Iveta Hynštová (FaSci MU) - topic: Anterior gradient protein family characterization, the determination of AGR3 protein expression in normal and tumor tissues.- supervisor BP: Mgr. Roman Hrstka, Ph.D. (completed 2011)
  • Jana Nováková (FaSci MU) - topic: The 14-3-3 protein family: the double-edged sword in cancer development.- supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2011)
  • Vendula Pernikářová (FaSci MU) - topic: High-resolution mass spectrometry with Orbitrap technology: New chances for proteomics. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2011)
  • Bc. Kateřina Ondrášková (FaSci MU) – topic: Hybrid electrochemically active organometallic compounds showing antitumor effects. – supervisor: doc. Mgr. Roman Hrstka, Ph.D.
  • Bc. Daniel Nesrsta (FaSci MU) – topic: Identification and evaluation of potential prognostic biomarkers of endometrial cancer. – supervisor DP: Mgr. Jitka Holčáková, Ph.D. (completed 2021)
  • Bc. Andrea Martišová (FaSci MU) – topic: Determination of epigenetic regulation of AGR2 expression in relation to metastasis development in colorectal cancer. – supervisor DP: doc. Mgr. Roman Hrstka, Ph.D. (completed 2020)
  • Bc. Iveta Klemešová (born Pacáčková) (FaSci MU) – topic: Identification of metastatic determinants in colorectal cancer. – supervisor: doc. Mgr. Roman Hrstka, Ph.D. (completed 2020)
  • Bc. Michaela Sládková (FaSci MU) - topic: Monoclonal B-cell lymphocytosis. - supervisor: Mgr. Kateřina Pilátová, Ph.D. (completed 2019)
  • Bc. Ondřej Vacek (FaSci MU) - topic: Role of extracellular localization of Hsp90 in cancer cells. - supervisor DP: Mgr. Michal Pastorek, Ph.D. (completed 2018)
  • Bc. Oliver Šimončík (FaSci MU) – topic: Regulation of stress response in cancer cells. - supervisor DP: MUDr. Petr Müller, Ph.D. (completed 2017)
  • Bc. Eliška Stuchlíková (FaSci MU) – topic: Profiling glycan structures isolated from ovarian cancer cell lines. - supervisor: prof. Ing. Lenka Hernychová, Ph.D. (completed 2017)
  • Bc. Lukáš Uhrík (FaSci MU) – topic: Production of recombinant enzymes and their use for studying structural changes of proteins. - supervisor: prof. Ing. Lenka Hernychová, Ph.D. (completed 2017)
  • Bc. Diana Bartáková (FaSci MU) - topic: Novel electrochemical approaches in molecular oncology. - supervisor: Mgr. Martin Bartošík, Ph.D. (completed 2018)
  • Bc. David Dzurický (FaSci MU) – topic: Study of chaperone complexes in tumor cells. - supervisor: MUDr. Petr Müller, Ph.D. (completed 2017)
  • Bc. Veronika Martinková (FaSci UPOl) - topic: Initial structural and functional analysis of LONRF3 protein. - supervisor: MUDr. Petr Müller, Ph.D. (completed 2016)
  • Bc. Radka Černochová (FaSci MU) - topic: Role of deltaNp63alpha in intracellular protein transport in breast cancer cells. - supervisor: Mgr. Jitka Holčáková, Ph.D (completed 2016)
  • Bc. Ludmila Jiráková (FaSci MU) – topic: Establishment and characterisation of colorectal carcinoma cell lines with decreased level of AGR2 protein. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2017)
  • Bc. Kateřina Ceralová (FaSci MU) - topic:Characterization of p63-positive cell populations in breast cancer-derived cell lines. - supervisor: Mgr. Marta Nekulová, Ph.D. (completed 2016)
  • Bc. Helena Ďuríková (FaSci MU) - topic: Development and evaluation of simple and quick assay for detection of HPVs. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2016)
  • Bc. Hedvika Fraňková (FaSci MU) - topic: Study of molecular mechanisms responsible for carcinogenesis of cervical cancer. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2016)
  • Bc. Jana Matějíková (FaSci MU) – topic: Bioelectroanalysis of microRNA and DNA methylation and its application in cancer diagnostics. - supervisor: Mgr. Martin Bartošík, Ph.D. (canceled)
  • Bc. Karolína Zoufalová (FaSci MU) - topic: Analysis of pro-metastatic signalling pathways in breast cancer. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2016)
  • Bc. Edita Zemanová (St. Elizabeth University College of Health and Social Work Bratislava) - topic: Implementation of pharmacogenetic and pharmacokinetic tests for predicting the toxicity associated with administration of fluoropyrimidines in clinical practice. - supervisor: Mgr. Martina Mrkvicová, Ph.D. (completed 2015)
  • Bc. Světlana Lučanová (FaSci MU) - topic: Study of structure changes of proteins using H/D exchange method connected with mass spectrometry and limited proteolysis. - supervisor: prof. Ing. Lenka Hernychová, Ph.D. (completed 2015)
  • Bc. Petra Kovaříková (FaSci MU) - topic: Carboxypeptidase B1 and its role in tumor biology. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2015)
  • Bc. Michal Řiháček (FaSci MU) – topic: Optimalization and validation of methotrexate, folate and homocysteine CSF levels determination in children with cancer as biomarkers of therapeutical effect and toxicity of systemic and intrathecal methotrexate. - supervisor: doc. MUDr. Dalibor Valík, Ph.D. (completed 2014)
  • Bc. Josef Maryáš (FaSci MU) - topic: Funkctional characterization or prometastatic proteins in breast carcinoma. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2014)
  • Bc. Dominika Černá (Fa chem-tech, Univ Pardubice) - topic: The study of structure changes of protein complex TOMM34 and Hsp70/90 by using H/D exchange approach. - supervisor: prof. Ing. Lenka Hernychová, Ph.D. (completed 2014)
  • Bc. Lucia Sommerová (FaSci MU) - topic: The role of AGR2 in the epithelial-mesenchymal transition. - supervisor: Mgr. Roman Hrstka, Ph.D (completed 2014)
  • Bc. Tereza Frostová (FaSci MU) - topic: SELDI-TOF MS profiling of pathogenic bacteria aimed at Enterobacteriaceae. - supervisor: RNDr. Lenka Dubská, Ph.D. (completed 2013)
  • Bc. Květa Pilařová (FaSci MU) - topic: The study of the role of AGR2 protein in cell lines derived from pancreas carcinoma.- supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2013)
  • Bc. Vendula Pernikářová (FaSci MU) - topic: The study on the cell stress in bakteria using modern method of quantitative proteomics. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2013)
  • Bc. Iveta Hynštová (FaSci MU) - topic: The study of mechanisms leading to the senescence of tumor cell: The role and the function of anterior gradient protein family. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2013)
  • Bc. Tereza Nehybová (FaSci MU) - topic: Analysis of anti-cancer properties of wedelolactone. - supervisor: Mgr. Petr Beneš, Ph.D. (completed 2013)
  • Bc. Gabriea Pavlasová  (FaSci MU) - topic: Effects of methotrexate on cell lines derived from solid tumors of the children's age. - supervisor: RNDr. Jakub Neradil, Ph.D. (completed 2013)
  • Bc. Pavlína Holešínská (FaSci MU) - topic: Transmembrane proteins as potential diagnostic and therapeutic targets in oncology. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2012)
  • Bc. Zuzana Volejníková (FaChT UPCE) - topic: The function properties of platelets in oncological patients. - supervisor: RNDr. Lenka Dubská, Ph.D. (completed 2012)
  • Bc. Jakub Faktor (FaSci MU) - topic: New quantitative proteomic approaches in oncology research. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2012)
  • Bc. Dominika Váňová (FaSci MU) - topic: Protein markers of metastatic potential in breasr carcinoma and their expression related to clinicipathological characteristics. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2011)
  • Mgr. Barbora Vavrušáková (FaSci MU) - topic: Influence of ER stress on immune surveillance in carcinogenesis. - supervisor DisP: prof. MUDr. Marek Svoboda, Ph.D.
  • Mgr. Miroslav Bardelčík (FaSci MU) – topic: Molecular mechanisms of response regulation to stress. – supervisor: MUDr. Petr Müller, Ph.D.
  • Mgr. Martina Kučeríková (FaSci MU) – topic: Mechanisms of non-mutational inactivation of p53 protein in human tumors. – supervisor: Mgr. Lucia Hároníková, Ph.D.
  • Ravery Jovinary Sebuyoya, MSc. (FaSci MU) – topic: Bioelectrochemistry in molecular oncology. – supervisor: Mgr. Martin Bartošík, Ph.D.
  • Mgr. Andrea Martišová (FaSci MU) – topic: The role of RNA-protein interactions in regulation of fundamental processes in tumor cell. - supervisor: doc. Mgr. Roman Hrstka, Ph.D.
  • Mgr. Adam Paulin Urminský (FaSci MU) – topic: Identification and quantification of N-glycoproteins in sera and tissues of oncological patients. – supervisor DP: prof. Ing. Lenka Hernychová, Ph.D.
  • Mgr. Nela Friedlová (FaSci MU) - topic: Funkce transmembránových proteinů indukovaných interferonem v nádorových buňkách. – supervisor DP: Mgr. Marta Nekulová, Ph.D.
  • Mgr. Václav Hrabal (FaSci MU) - topic: Studium interakcí proteinové rodiny p53 v normálních a nádorových buňkách. – supervisor DP: RNDr. Bořivoj Vojtěšek, DrSc.
  • Ashita Singh (FaSci MU) – topic: Role of lithocholic acid-induced cell signalling in oesophageal cancer progression model. – supervisor: RNDr. Bořivoj Vojtěšek, DrSc.
  • Mgr. Oliver Šimončík (FaSci MU) – topic: Regulation of gene expression in response to proteotoxic stress. – supervisor: MUDr. Petr Müller, Ph.D.
  • Mgr. Radovan Krejčíř (FaSci MU) - topic: Study of molecular and functional mechanism of novel cytostatics (derivates of polymethinium salts). - supervisor: RNDr. Bořivoj Vojtěšek, DrSc.
  • Mgr. Ludmila Moráňová (FaSci MU) - topic: Development of bioelectrochemical methods for in vitro diagnostics of tumor diseases. - supervisor: Mgr. Martin Bartošík, Ph.D.
  • Mgr. Lukáš Uhrík (FaSci MU) – topic: Proteomic analysis of medulloblastoma molecular subgroups: discovery of novel clinically relevant markers. - supervisor: prof. Ing. Lenka Hernychová, Ph.D.
  • Mgr. Lenka Dosedělová (FaSci MU) - topic: Identifying novel secretory pathways driving human cancer metastasis. - supervisor: prof. Ing. Lenka Hernychová, Ph.D.
  • Mgr. Veronika Vandová (FaSci MU) – topic: Analysis of proteotoxic stress in cancer cell. - supervisor: MUDr. Petr Müller, Ph.D.
  • Mgr. Michaela Galoczová (FaSci MU) - topic: p63 signalling in tumors. - supervisor: RNDr. Bořivoj Vojtěšek, DrSci.
  • Mgr. Hana Skoupilová (FaSci MU) - topic: The role of endoplasmic reticulum stress in cancer cell. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2021)
  • Mgr. Lucia Sommerová (FaSci MU) - topic: The role of Anterior gradient proteins in EMT. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2018)
  • MUDr. Beatrix Bencsiková (FaMed MU) - topic: Angiogenesis in tumors: evaluation of predictive factors in patiens with colorectal cancer. - supervisor: prof. MUDr. Rostislav Vyzula, CSc. (completed 2016)
  • MUDr. Radka Obermannová - (FaMed MU) - topic: Circulating blood levels of 25-hydroxycholecalciferol monitored in the course of first-line chemobiotherapy for metastatic colorectal cancer and their relevance to overall survival. - supervisor: doc. MUDr. Dalibor Valík, Ph.D. (completed 2017)
  • MUDr. Pavel Krupa (FaMed MU) - topic: Hypofractionated accelerated radiotherapy of prostate cancer. - supervisor: prof. MUDr. Pavel Šlampa, Ph.D. (completed 2016)
  • Mgr. Josef Maryáš (FaSci MU) - topic: Molecular interactions in tumor metastastis and their studying with the use of functional proteomics. - supervisor: Mgr. Pavel Bouchal, Ph.D. (terminated)
  • Mgr. Dominika Coufalová (FaSci MU) - topic: Study of structure changes of oncoproteins by mass spectrometry. - supervisor: prof. Ing. Lenka Hernychová, Ph.D. (completed 2020)
  • MUDr. Ján Podhorec (FaMed MU) - topic: The role of AGR2 protein and of its regulation in relation to inflammatory processes. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc.
  • Mgr. Adam Krejčí (FaSci MU) – topic: The use of global analysis of peptide libraries to identify new biomarkers and anticancer drugs. - supervisor: MUDr. Petr Müller, Ph.D. (completed 2018)
  • Mgr. Martina Zahradníková (FaSci MU) - topic: Study of glycoproteins expressed on surface of cancer cells. - supervisor: prof. Ing. Lenka Hernychová, Ph.D.
  • Mgr. Veronika Brychtová (FaMed MU) - topic: The analysis of the role of AGR2 and AGR3 proteins in cancer cell and the determination of their expression in selected tumor tissues. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2014)
  • Mgr. Lucie Kafková (FaMed MU) - topic: Tumor multiplicity - etiopathogenesis, differencial diagnostics and treatment. - supervisor: prof. MUDr. Rostislav Vyzula, CSc. (completed 2016)
  • Mgr. Filip Trčka (FaSci MU) - topic: The role of chaperone system for malignant transformation of the cell. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2015)
  • Mgr. Eva Růčková (FaSci MU) - topic: The role of stress proteins in stabilization and degradation of p53 protein and its isoforms. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2014)
  • Mgr. Marta Nekulová (FaSci MU) - topic: Te role of p63 isoforms in malignant transformation of the cell. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2014)
  • Mgr. Eva Matoulková (FaSci MU) - topic: The role of AGR2 and AGR3 proteins in cancer cell in response to stress conditions. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2017)
  • Mgr. Michal Ďurech (FaSci MU) - topic: The application of chaperone system inhibition for cancer therapy. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2016)
  • Mgr. Monika Dvořáková (FaSci MU) - topic: Molecular mechanisms of metastasis: Integrated genomics and proteomics approaches. - supervisor: Mgr. Pavel Bouchal, Ph.D.
  • Mgr. Iva Procházková  (FaSci MU) - topic: The study of molecular regulatory mechanisms using proteomic approaches. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2019)
  • Mgr. Kateřina Pilátová (FaMed MU) - topic: The use of proteomics in the study of tumor angiogenesis. - supervisor: doc. MUDr. Dalibor Valík, Ph.D. (completed 2018)
  • MUDr. Tereza Plesková (FaMed MU) - topic: Pharmacogenetic aspects of the treatment of solid tumors with fluoropyrimidins. - supervisor: doc. MUDr. Dalibor Valík, Ph.D.
  • Joanna Obacz, MSc. (FaSci MU) - topic: The study of function of AGR3 protein and of the mechanisms responsible for the regulation of its expression in tumor cell. - supervisor: Mgr. Roman Hrstka, Ph.D. (completed 2016)
  • Paulina Orzol, MSc. (FaSci MU) - topic: The protein p63 and its contribution to the phenotype of the tumor stem cell. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2016)
  • Mgr. Mariana Pjechová (FaSci MU) - topic: Proteomics and phage display analysis of novel HCMV immunomodulating functions and their contribution to HCMV pathogenesis. - supervisor: RNDr. Bořivoj Vojtěšek, DrSc. (completed 2020)
  • Mgr. Jakub Faktor (FaSci MU)  - topic: Targeted proteomics, a new approach for protein quantitation in tumor biology. - supervisor: Mgr. Pavel Bouchal, Ph.D. (completed 2018)

6Software

Bioinformatics software tools developed in RECAMO

Adam Krejčí (RECAMO, Masaryk Memorial Cancer Institute, 2016)

Hammock is a tool for peptide sequence clustering. It is able to cluster extremely large amounts of short peptide sequences into groups sharing sequence motifs. Typical Hammock applications are NGS-based experiments using large combinatorial peptide libraries, e.g. Phage display.

Filip Zavadil-Kokáš (RECAMO, Masarykův onkologický ústav, 2018) (RECAMO, Masaryk Memorial Cancer Institute, 2018)

TransPEM (Software for Translation sequence into peptide based on mutation information) is a novel bioinformatics tool which was developed for providing mutated and wild type sequences based on bioinformatics analysis of single nucleotide polymorphisms. Protein sequences can serve as an input for proteomics analysis. This software provides fast and reliable extracting of coding sequences (CDS) from genome and their translation into proteins with respect to the information about mutations. It is suitable for any number of sequences and as an user-friendly software requires only the basic knowledge of a Linux operating system.

Iveta Selingerová, Marie Langrová (RECAMO)

Kernhaz is the package created for the statistical software R, available from the official archive CRAN. This package implements estimates of hazard function for right-censored data. These estimates are smooth functions based on kernel methods. The risk of an event (death, relapse,…) is estimated as time-dependent or moreover depending on some covariate (age, tumor volume,…). The package includes also two bandwidth selection methods.

For further information and downloads click here.

 Iveta Selingerová (RECAMO, Department of Mathematics and Statistics, SCI MU)

Kernhaz for MATLAB is the package of M-functions created as an alternative to R package kernhaz for MATLAB users. This package implements estimates of hazard function for right-censored data. These estimates are smooth functions based on kernel methods. The risk of an event (death, relapse,…) is estimated as time-dependent or moreover depending on some covariate (age, tumor volume,…). The package includes also two bandwidth selection methods.

Iveta Selingerová, Kateřina Pilátová, Michal Řiháček, Martina Mrkvicová, Lenka Zdražilová Dubská

The package of computing tools created in MS Excel using VBA. The tools are created following the recommendation of the professional societies (Czech Society of Clinical Biochemistry, Czech Society of Haematology, SEKK). They can be used as forms for evaluation of measurement uncertainties or reproducibility in clinical laboratories. Detailed manual for filling and application examples are included. The tool for reproducibility is included in two variants – for 20 or 50 measured values.

7Publications

You may also be interested in...

Foreign nationals and self-payers

Free Cancer Helpline

Monday – Friday from 7.30 AM to 3.00 PMn

(+420)800 222 322

Loading...

Upozornění

Pozor, v souvislosti s uzavřením spodních parkovišť (nad vodojemy) dochází od 1.6.2023 k velkým změnám v parkování v okolí MOÚ. Nově jsou zřízeny zóny pro možnost rychlého vystoupení a nastoupení chodících pacientů (tzv. Kiss+Ride), kde však nelze auto nechat stát. Dále jsme zavedli zóny pro vystoupení a nastoupení pacientů potřebujících transportní sedačku nebo lůžko.

Další informace, včetně mapy, naleznete zde.

 

beru na vědomí, vstoupit na web